Novo Nordisk (NVO) lifts 2026 outlook; shares surge as Wegovy drives growth

Novo Nordisk (NVO) has raised its 2026 revenue outlook substantially, attributing this increase primarily to the strong performance of its weight-loss drug, Wegovy. The company reported a 20% year-on-year increase in sales for the most recent quarter, reaching DKK 54 billion. Following this announcement, NVO shares experienced a notable surge in trading volumes, reflecting increased investor confidence. This revision implies positive implications for future earnings and market position, particularly in the growing obesity management sector.